Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4

被引:0
作者
Oskola, E. V. [1 ]
Shubina, A. T. [1 ]
Karpov, Yu. A. [1 ]
机构
[1] Inst Clin Cardiol, Moscow, Russia
关键词
angioprotection; type 2 diabetes mellitus; dipeptidyl peptidase-4 inhibitors; incretins; DEPENDENT INSULINOTROPIC POLYPEPTIDE; TYPE-2; DIABETES-MELLITUS; LIPOPROTEIN-LIPASE ACTIVITY; GLUCAGON-LIKE PEPTIDE-1; NITRIC-OXIDE RELEASE; CARDIOVASCULAR SAFETY; ENDOTHELIAL FUNCTION; GLYCEMIC CONTROL; ADIPOSE-TISSUE; SITAGLIPTIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) is a major health problem in all developed countries. It contributes to the development of atherosclerosis and increases the risk of cardiovascular events so blood glucose level correction is essential to preventing these complications. The relatively new and promising class of anti-diabetic drugs is dipeptidyl peptidase-4 inhibitors. By improving carbohydrate metabolism, they have angioprotective effects, such as anti-inflammatory and anti-atherosclerotic ones, including atherosclerotic plaque stabilization, improve endothelial function, lower blood pressure, and reduce the severity of albuminuria, which may have clinical implications for the prevention of macrovascular complications of type 2 DM.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 50 条
[31]   Cardiovascular safety of dipeptidyl peptidase-4 (DPP-4) inhibitors [J].
Gumprecht, Janusz .
CLINICAL DIABETOLOGY, 2015, 4 :19-24
[32]   Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks? [J].
Giuseppe Paolisso ;
Matteo Monami ;
Raffaele Marfella ;
Maria Rosaria Rizzo ;
Edoardo Mannucci .
Advances in Therapy, 2012, 29 :218-233
[33]   Determination of Dipeptidyl Peptidase-4 Inhibitors by Spectrophotometric and Chromatographic Methods [J].
P. B. Deshpande ;
S. R. Butle .
Journal of Analytical Chemistry, 2018, 73 :303-316
[34]   Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors [J].
Tanaka, Atsushi ;
Node, Koichi .
CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
[35]   Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis [J].
Scheen, Andre .
EXPERT OPINION ON DRUG SAFETY, 2013, 12 (04) :545-557
[36]   Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors [J].
Mulvihill, Erin E. ;
Drucker, Daniel J. .
ENDOCRINE REVIEWS, 2014, 35 (06) :992-1019
[37]   Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach [J].
Dai, Yao ;
Dai, Dongsheng ;
Mercanti, Federico ;
Ding, Zufeng ;
Wang, Xianwei ;
Mehta, Jawahar L. .
ACTA DIABETOLOGICA, 2013, 50 (06) :827-835
[38]   Determination of Dipeptidyl Peptidase-4 Inhibitors by Spectrophotometric and Chromatographic Methods [J].
Deshpande, P. B. ;
Butle, S. R. .
JOURNAL OF ANALYTICAL CHEMISTRY, 2018, 73 (04) :303-316
[39]   Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment [J].
Davis, T. M. E. .
DIABETES OBESITY & METABOLISM, 2014, 16 (10) :891-899
[40]   Dipeptidyl Peptidase-4 Inhibitors - Emerging Player for Vascular Protection [J].
Satoh, Kimio .
CIRCULATION JOURNAL, 2013, 77 (05) :1156-1157